tbuckley/cabot-search huggingface dataset:
Correction: Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease
Journal: Annals of Internal Medicine (2002)

Corrections20 August 2002Correction: Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal DiseaseFREESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-4-200208200-00028 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In an article on angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease (1), the normal mean value for urine protein excretion, given in the first full sentence on page 83, should be 0.05 g/d (50 mg/d), not 0.5 g/d.Reference1. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al . Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73-87. [PMID: 11453706] LinkGoogle Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAngiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease Tazeen H. Jafar , Christopher H. Schmid , Marcia Landa , Ioannis Giatras , Robert Toto , Giuseppe Remuzzi , Giuseppe Maschio , Barry M. Brenner , Annelise Kamper , Pietro Zucchelli , Gavin Becker , Andres Himmelmann , Kym Bannister , Paul Landais , Shahnaz Shahinfar , Paul E. de Jong , Dick de Zeeuw , Joseph Lau , Andrew S. Levey , and Metrics 20 August 2002Volume 137, Issue 4Page: 299KeywordsAngiotensin converting enzyme inhibitorExcretionProteinsRenal diseasesUrine ePublished: 20 August 2002 Issue Published: 20 August 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Drug Substitution
Authors: Claude A. Frazier
Journal: JAMA (1979)

<h3>To the Editor.—</h3> The reasoning behind prescribing and filling prescriptions with generic drugs rather than by trade name is good, but there are also problems to be considered, especially perhaps for the patient with allergies. A patient of mine who is hypersensitive to tartrazine recently ran afoul of the generic-trade name issue. I had prescribed metaproterenol sulfate (Alupent), 10 mg, two pills to be taken three to four times a day. Food, Drug, and Cosmetic yellow dye No. 5 (tartrazine) is absent in this particular preparation. However, when she took the prescription to a pharmacist, he filled it with Alupent, 20 mg, which my patient noted was gray instead of white. When she asked about the possibility of tartrazine in the pills, she was informed that there was none, and they would be the same as was called for in the prescription, with the exception that she would need to
Abortion
Authors: P. A. Lohr, M. Fjerstad, U. DeSilva, R. Lyus
Journal: BMJ (2014)

<h3>Introduction</h3> Infective endocarditis (IE) is associated with high mortality and morbidity. Multiple organ failure is the main cause of death after surgery for IE. Cardiopulmonary bypass (CPB) can cause a systemic inflammatory response. In a pilot study (REMOVE-pilot (Revealing mechanisms and investigating efficacy of hemoad-sorption for prevention of vasodilatory shock in cardiac surgery patients with infective endocarditis – a multicentric randomized controlled group sequential trial)), we found that plasma profiles of cytokines during and after CPB were higher in patients with IE compared with patients with non-infectious valvular heart disease. Sequential Organ Failure Assessment (SOFA) scores on the first and second postoperative days and in-hospital mortality were also higher in IE patients. This protocol describes the design of the REMOVE trial on cytokine-adsorbing columns, for example, CytoSorb, for non-selective removal of cytokines. The aim of the REMOVE study is to demonstrate efficacy of CytoSorb on the prevention of multiorgan dysfunction in patients with IE undergoing cardiac surgery. <h3>Methods and analysis</h3> The REMOVE study is an interventional randomised controlled multicenter trial with a group sequential (Pocock) design for assessing efficacy of CytoSorb in patients undergoing cardiac surgery for IE. The change in mean total SOFA (∆ SOFA) score between preoperative and postoperative care will be used as primary endpoint. Data on 30-day mortality, changes in cytokines levels, duration of mechanical ventilation, length of intensive care unit and hospital stay, and postoperative stroke will be collected as secondary endpoints. An interim analysis will be conducted after including 25 participating patients per study arm (with a focus on feasibility of the recruitment as well as differences in cytokines and cell-free DNA levels). <h3>Ethics and dissemination</h3> The protocol was approved by the institutional review board and ethics committee of the University of Jena as well as by the corresponding ethics committee of each participating study centre. The results will be published in a renowned international medical journal, irrespective of the outcomes of the study. <h3>Trial registration number</h3> The ClinicalTrials.gov registry (NCT03266302).
Evaluation of Two Antineoplastic Agents
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LETTER FROM NEW YORK.
Authors: None P. B. P.
Journal: JAMA (1889)

(FROM OUR OWN CORRESPONDENT.) The New Mausoleum Plan for the Disposal of the Dead—Dr. John M. Peacocke and Dr. A. N. Bell discuss the subject—Executions by Electricity— Dr. Wm. A. Hammond and the Brown-Séquard Elixir. Of late the new mausoleum plan of disposal of the dead has attracted considerable attention in this city. The project seems likely to meet with much favor both from sanitarians and the public at large, and a company, in which many clergymen and physicians are interested, has now been organized for the purpose of erecting suitable buildings in the leading cities of the country. While the objections to the prevalent mode of disposal of the dead are generally recognized, cremation meets with much opposition, and it is believed that this new sanitary system will be widely adopted as a substitute for burial. The buildings, each of which will contain from ten to forty thousand sepulchral
Utilization review conference. Discussion. Morning session
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sickle Cell Politics
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMA Psychiatry
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Tracy Frey, Iris Lo, Kevin Brown, Amanda Ehrhardt, M Newman, Suzanne Walker, Connie Manno Senior, Sara Billings, Timothy Gray, Juliet Orellana, Paul Ruich, Kirby Snell, Catherine Alden, Stephanie Beckmeyer, Jane Calayag, Jan Clavey, Mary Coerver-Connolly, Paula Glitman, Laura King, Regina Lilly, Charon Pierson, Rebecca Ritke, Thressa Smith, Divya Sreekumar, Donna Thordsen, Christine Tilles, Caroline Woods, Editorial Assistant, Wanda Hill, Larry Bryant, Jacob Kendall-Taylor, Monica Mungle, Fanny Brown, Anna Bukowski, Lee Calibeo, Lenette Gardner-Gullens, Tosca Hall, Erin Kato, Rachell Lozano, Caroline Sietmann, Angelia Scientifi, Michael Berkwits, Eric Butkus, Jesse Mcquarters, Elena Guobyte, Emily Ling, Daniel Morrow, Hasaballa Ally, Reuben Rios, Mary Ferkaluk, Karen Bucher, Andy Rekito, Nick Reback, Lohitha Kethu, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Deanna Bellandi, Jim Michalski, Sara Dibari, Martin Paulus, Helen Simpson, New York, Stewart Anderson, Helena Chmura Kraemer, Palo Alto, California Lee, David Rosenfi Eld, Guido Schwarzer, Jama Network, Howard Bauchner
Journal: JAMA Psychiatry (2020)
EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).
Authors: Ian D. Davis, Anne Long, Andrew Martin, David Espinoza, Sonia Yip, Ganessan Kichenadasse, Jennifer F. Thompson, Michelle L. Harrison, Raymond M. Lowenthal, Nick Pavlakis, Arun Azad, George Kannourakis, Christopher Steer, David Goldstein, Jeremy David Shapiro, Martin R. Stockler
Journal: Journal of Clinical Oncology (2014)

438 Background: We hypothesized that alternating inhibitors of the VEGFR and mTOR pathways would delay the development of resistance in aRCC. Methods: Single-arm, two-stage, multicenter, phase II trial to determine the activity, feasibility, and safety of sunitinib 50mg daily 4 weeks (wk) on / 2wk off, alternating with everolimus 10mg daily for 5 wk on / 1 wk off. Participants had aRCC of MSKCC good or intermediate risk. Primary endpoint: proportion alive and free of progression at 6 months (PFS6m). Secondary endpoints included feasibility, tumour response, overall survival (OS), and adverse events (AE). Imaging was done every 6 wk till wk 24, then q12wk. Planned sample size of 55 allowed distinction between a PFS6m rate of ≤64% versus ≥84% with type 1 and type 2 error rates of 5%. Results: We recruited 55 eligible participants from Sept 2010 to Aug 2012: mean age 61, male 71%, good risk 16%, intermediate risk 84%. Feasibility: 80% could start cycle 2 within 14 weeks; 64% received ≥22 weeks of alternating therapy; 78% received ≥22 wks of any treatment. Efficacy: PFS6m was 29/55 (53%; 95% CI: 40%-66%). The OR rate was 7/55 (13%; 95% CI 4%-22%, all partial). After a median follow-up of 20 months, 47 of 55 had progressed with a median PFS of 8 months (95% CI: 5 to 10), and 30 of 55 had died with a median OS of 17 months (95% CI: 12 to undefined). Safety: AEs were consistent with those expected for each single agent. The most common grade 3 or 4 AE (number of participants) were hypertension (13), anaemia (9), oral mucositis (7), fatigue (n=7), GGT increase (n=6), pain (n=5), and platelet count decreased (n=5). Conclusions: The EVERSUN regimen was feasible and safe, but its activity did not meet prespecified values to warrant further research. This study supports the current approach of continuing first line anti-VEGF therapy until progression or prohibitive toxicity before switching to another drug. EVERSUN is an ANZUP Cancer Trials Group Ltd. trial coordinated by the NHMRC Clinical Trials Centre (ACTRN12609000643279). Clinical trial information: ACTRN12609000643279.
NEW INEBRIATE ASYLUMS.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study
Authors: D. Rossini, C. Cremolini, F. Morano, R. Berenato, E. Tamborini, F. Perrone, R. Moretto, A. Gloghini, A. Busico, G. Zucchelli, C. Baratelli, E. Tamburini, G. Fucà, C. Volpi, M. Milione, M. Di Maio, G. Fontanini, F. de Braud, A. Falcone, F. Pietrantonio
Journal: Annals of Oncology (2017)
Errors in Course Listings
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3244: Design, synthesis and biological evaluation of substituted furo[2,3-d]pyrimidines as potent microtubule targeting antitumor agents that circumvent Pgp and βIII-tubulin mediated resistance
Authors: Aleem Gangjee, Xin Zhang, Ojas Namjoshi, Ravi Kumar Vyas Devambatla, Ernest Hamel, Susan L. Mooberry
Journal: Cancer Research (2011)

Abstract Despite the unprecedented success of microtubule targeting agents such as paclitaxel in cancer chemotherapy, overexpression of P-glycoprotein (Pgp) and/or βIII-tubulin can cause clinical resistance to these agents. This limits their utility as cancer chemotherapeutic agents. In addition, several antitubulin agents, particularly the taxoids, have poor water solubility, so that their administration requires formulations that generate hypersensitivity reactions. Recently, we reported two analogs based on 2,6-dimethylcyclopenta[d]pyrimidine and pyrrolo[2,3-d]pyrimidine scaffolds that circumvent both these drawbacks. To study the structure-activity relationship of these new antimitotic agents, we have designed furo[2,3-d]pyrimidines as isosteres of pyrrolo[2,3-d]pyrimidines. We synthesized 2-methyl- and 2-desmethylfuro[2,3-d]pyrimidines AG1 and AG16 from the corresponding 4-chloro and 4-amino analogs, respectively, by treatment with N-methyl-4-methoxyaniline or with 4-methoxyiodobenzene followed by N4-methylation. The synthesis of the 4-chloro analog involved the reaction between acetamidine chloride and diethyl 2-(prop-2-ynyl)malonate in the presence of sodium metal, followed by base-catalyzed cyclization and chlorination. The 4-amino analog was synthesized by treating 1-hydroxypropan-2-one with malononitrile followed by cyclization using formamidine. The compounds AG1 and AG16 inhibit the growth of all the tumor cells in the NCI 60-cell panel with two-digit nanomolar GI50 values and also depolymerize cellular microtubules at low nanomolar concentrations. These compounds inhibit the assembly of purified tubulin (AG1, IC50 = 1.9 ± 0.1 µM; AG16, IC50 = 3.3 ± 0.5 µM) and the binding of colchicine to tubulin (AG1, 63% inhibition at 1 µM, 86% at 5 µM; AG16, 71% at 1 µM, 96% at 5 µM). These compounds are fully active in tumor cells overexpressing either Pgp or βIII-tubulin, thus overcoming two important mechanisms associated with tumor resistance to paclitaxel. We have thus identified a potentially important new scaffold, the furo[2,3-d]pyrimidine, for antitubulin agents. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3244. doi:10.1158/1538-7445.AM2011-3244
TETANUS AFTER VACCINATION.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Legionnaires' disease associated with a hospital water system. A five-year progress report on continuous hyperchlorination
Authors: C. M. Helms
Journal: JAMA (1988)

In 1981, sixteen cases of nosocomial legionellosis occurred among 456 patients admitted to a new hematology-oncology unit (35 per 1000 admissions). Monoclonal antibody typing and restriction endonuclease plasmid analysis identified a unique strain (09,04) of<i>Legionella pneumophila</i>serogroup 1 isolated from both patients and water outlets. Continuous hyperchlorination of the hot and cold water began in January 1982, and chlorine levels of 3 to 5 mg/L have been maintained most recently. Water samples have been consistently negative for<i>Legionella</i>for more than five years. Four sporadic cases of nosocomial legionellosis have occurred in the hematology-oncology unit during the same period (one per 1000 admissions) associated with a different strain of<i>L pneumophila</i>serogroup 1 (09,00). The environmental reservoir(s) of<i>L pneumophila</i>serogroup 1 in these cases has not been identified. Levels of trihalomethanes (potential carcinogens) were high (&gt;100 μg/L) when chlorine levels of hot water exceeded 4 mg/L. Some corrosion damage to the water distribution system has occurred: the average number of leaks per month increased steadily from zero in 1982 to 5.2 in 1986. The chlorinator installation costs were $75 800, and annual operation expenses were $12 500. Continuous hyperchlorination is a promising but still experimental technique for control of nosocomial legionellosis. In our experience, epidemic disease has been controlled, but sporadic cases have continued to occur. (<i>JAMA</i>1988;259:2423-2427)